Sino Biopharm's TQC3721 receives approval for phase III COPD study

Sino Biopharmaceutical Limited (HKEX:1177) announced that its innovative drug, TQC3721 inhalation suspension, has been approved by China's Center for Drug Evaluation (CDE) for Phase III registrational clinical study. The study will focus on the maintenance treatment of COPD. TQC3721, an inhaled PDE3/4 inhibitor, offers both bronchodilatory and anti-inflammatory effects, with clinical study data showing significant improvement in bronchodilation and St. George's Respiratory Questionnaire scores compared to drugs with the same target. This Phase III trial will further assess the efficacy and safety of TQC3721 across various background treatments in a larger patient sample. The company notes that COPD is a major global health challenge, affecting approximately 100 million people in China.